TEM (Tempus AI, Inc.) Market Value to Book Value Ratio
Tempus AI, Inc (TEM) combines oncology experts and AI to personalize medicine, driving growth through options. The company minimizes its environmental footprint by transitioning computing to green energy, while a network effect is created through data exchange between clinics and pharma behemoths. This P/B ratio chart demonstrates the market reaction to corporate news, with the indicator currently standing at 27.38.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_TEM_-_Tempus-AI-Inc_-_Capitalization-to-Book-Value-Ratio "TEM Tempus AI Market Capitalization to Book Value Ratio (06/15/2024 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for tempus.com (TEM)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:TEM Tempus AI, Inc.
The complex cold-chain logistics for biomaterials at Tempus AI, Inc (TEM) significantly increase capital expenditures, establishing a real asset base for sequencing. By analyzing the price-to-book ratio, an investor determines the multiple of the market price relative to net assets, which allows for an assessment of the business premium or the identification of capital undervaluation risks.
Main competitors
Market Capitalization to Book Value Ratio Qiagen N.V.|IONS (ionispharma.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Repligen (RGEN)|Capitalization to Book Value Ratio Avidity Biosciences Inc|Market Capitalization to Book Value Ratio CRSP|Market Capitalization to Book Value Ratio GeneDx Corp WGS|Market Cap to Net Assets Ratio Ultragenyx Pharmaceutical (RARE)|Market Cap to Book Value Multiple beamtx.com BEAM|SRPT (Sarepta) - Market Capitalization to Book Value Ratio|TWST: Market-to-Book Ratio|TXG (10x Genomics Corp) - Market Value to Book Value Ratio|NTLA (Intellia Corp) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Stoke Therapeutics STOK|Market Capitalization to Net Assets biolifesolutions.com (BLFS)|Market Cap to Net Assets Ratio WVE|Market Capitalization to Book Value Ratio MAZE (Maze Therapeutics, Inc.)|Market Value to Book Value Ratio SION|PRME - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Taysha Gene Therapies (TSHA)|QURE - Market Value to Book Value|MGTX: Market Capitalization to Book Value Ratio|REGENXBIO Inc (RGNX) - Market Capitalization to Book Value Ratio|SLDB: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ocugen Pharma (OCGN)|Pacific Biosciences (PACB) - Market Cap to Net Assets Ratio|Market Value to Book Value benitec.com (BNTC)|Market Capitalization to Book Value Ratio DSGN|Rocket Pharma - Market Capitalization to Book Value|4D Molecular Therapeutics Inc (FDMT) - Market Value to Book Value Ratio|LXEO - Capitalization to Book Value Ratio|KRRO (korrobio.com) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio editasmedicine.com|Silence Therapeutics plc (SLN) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple ProQR Therapeutics NV|Codexis, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio SGMO (Sangamo BioSciences)|Nautilus Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio metagenomi.co MGX|Precision BioSciences (DTIL) - Market Capitalization to Book Value Ratio|GBIO: Capitalization to Book Value Ratio|Market Value to Book Value Ratio Boundless Bio, Inc|Exicure (XCUR) - Capitalization to Book Value Ratio|IMNN (Imunon Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio RXi Pharmaceuticals (PHIO)|Market Cap to Net Assets Ratio Mustang Bio, Inc.|Market Cap to Book Value Multiple transcodetherapeutics.com (RNAZ)|BNGO: Market Capitalization to Book Value Ratio|Applied DNA Corp - Market-to-Book Ratio|BLUE: Market Value to Book Value Ratio|IPA: Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Omega Therapeutics, Inc. (OMGA)|Market Capitalization to Net Assets Singular Genomics Systems, Inc.|RGLS (Regulus Therapeutics Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio SYRS|TBIO (Telesis Bio, Inc.) - Market Value to Book Value Ratio|Market Capitalization to Book Value traconpharma.com TCON|Market Cap to Net Assets Ratio Unity Biotechnology, Inc.